A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

A third dose of CVnCoV, a former candidate mRNA vaccine against SARS-CoV-2, was previously shown to boost neutralizing antibody responses against SARS-CoV-2 wild-type in adults aged 18–60 and >60 years in a phase 2a clinical study. In the present study, we report the neutralizing antibody respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolz, Olaf-Oliver, Kays, Sarah-Katharina, Junker, Helga, Koch, Sven D., Mann, Philipp, Quintini, Gianluca, von Eisenhart-Rothe, Philipp, Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025705/
https://www.ncbi.nlm.nih.gov/pubmed/35455257
http://dx.doi.org/10.3390/vaccines10040508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025705/
https://www.ncbi.nlm.nih.gov/pubmed/35455257
http://dx.doi.org/10.3390/vaccines10040508

Ejemplares similares